Researchers have made a promising breakthrough in the fight against two of the most aggressive and treatment-resistant cancers: glioblastoma (GBM) and triple-negative breast cancer (TNBC). The study, conducted in collaboration with Polymer Factory, explored new ways to deliver cancer drugs more effectively using advanced polymer-based nanocarriers.
Treating GBM and TNBC is notoriously difficult. Traditional chemotherapy struggles with issues such as poor drug solubility, toxicity, and, in the case of brain tumors, the blood-brain barrier - a natural defense that blocks many drugs from reaching the tumor.
To tackle these challenges, the research team tested two innovative drug delivery systems:
These nanocarriers were designed to encapsulate and transport common chemotherapy agents like docetaxel, carboplatin, and doxorubicin, increasing their stability and effectiveness. The results were encouraging:
- DNGs were especially effective at delivering water-soluble drugs, offering high loading capacity.
- Micelles improved solubility and uptake of water-insoluble drugs like docetaxel.
- Both systems showed strong tumor penetration and significantly reduced cancer cell growth in
laboratory tests.
"This study represents a meaningful step forward in precision oncology," said Mats Wallnér, CEO of Polymer Factory. "By improving how cancer drugs are delivered, we can potentially make treatments both safer and more effective for patients with hard-to-treat tumors."
The findings not only offer hope for future cancer therapies but also highlight the potential of polymer-based nanotechnology in personalized medicine.
This disclosure contains information that Polymer Factory is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 08-08-2025 08:55 CET.